Format

Send to

Choose Destination
Cancer Med. 2017 Dec;6(12):2787-2795. doi: 10.1002/cam4.1228. Epub 2017 Oct 13.

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.

Author information

1
Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China.

Abstract

Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine-threonine kinases. However, Sorafenib is expensive, and clinical experience shows that it is not an effective treatment for many patients. Previous study has demonstrated that phosphorylated ERK (pERK) is a key downstream component in the RAF/MEK/ERK signaling pathway. Here, we investigate whether pERK is a useful biomarker for treating HCC with Sorafenib. In vitro cell viability assays showed that the efficacy of Sorafenib was distinctly different according to the level of pERK. Furthermore, in established patient-derived xenografts from HCC specimens, we found that the growth rate of tumors with high levels of pERK was significantly decreased by Sorafenib treatment. Taken together, pERK is a potential biomarker for the sensitivity to Sorafenib in treating HCC.

KEYWORDS:

Biomarkers; Hepatocellular carcinoma; Phosphorylated ERK; Sorafenib

PMID:
29030911
PMCID:
PMC5727337
DOI:
10.1002/cam4.1228
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center